Bisphophonates in CKD patients with low bone mineral density

Area of Science:

• Nephrology
• Endocrinology
• Orthopedics

Background:

• Chronic kidney disease-mineral and bone disorder (CKD-MBD) increases fracture risk due to low bone density and quality.
• Differentiating CKD-MBD from osteoporosis in low bone mineral density is challenging, often requiring bone biopsy.
• Bisphosphonates are generally safe for glomerular filtration rates ≥30 mL/min, but advanced CKD poses risks.

Purpose of the Study:

• To evaluate the safety and efficacy of bisphosphonates in patients with CKD-MBD.
• To highlight the challenges in differentiating CKD-MBD from osteoporosis.
• To emphasize the need for caution when prescribing bisphosphonates in advanced CKD.

Main Methods:

• Literature review on bisphosphonate use in CKD patients.
• Analysis of risks associated with bisphosphonate therapy in advanced CKD.
• Discussion of diagnostic challenges and treatment considerations.

Main Results:

• Bisphosphonates can be beneficial for CKD-MBD patients with GFR ≥30 mL/min.
• Advanced CKD increases the risk of low bone turnover disorders (osteomalacia, adynamic bone) and hyperparathyroidism aggravation.
• Bone biopsy is crucial in advanced CKD before bisphosphonate prescription.
• Vitamin D may help manage potential hypocalcemia.
• Benefits on vascular calcification are less likely in stages 3-4 CKD.

Conclusions:

• Bisphosphonate use in advanced CKD requires significant caution due to potential adverse effects.
• Bone biopsy is an important consideration before initiating bisphosphonates in advanced CKD.
• Further clinical investigations are needed to fully understand bisphosphonate effects in advanced CKD patients.